Inflammatory myopathies

Nailfold videocapillaroscopy findings are associated with Idiopathic inflammatory myopathy (IIM) subtypes and IFN activation

Arthritis Res TherPublished Cross-sectional study

Authors' conclusion

IIM patients exhibit distinct NVC abnormalities, which vary across different MSA subtypes.

Study context

Population
Patients with IIM, single centre
Participants
55 patients
Exposure
Nailfold videocapillaroscopy (NVC) features across myositis-specific antibody (MSA) subgroups: MDA5 vs ARS vs MSA
Outcome
NVC features in IIM subtypes and correlations with MSA subtypes, disease activity, cytokine profiles and ISG expression
Methodological detailsobservational, single-centre
  • Observational
  • Single-centre

Main finding

As reported in the abstract

NVC scores, MDA5(+) vs ARS(+)
  • NVC abnormalities observed in most IIM patients, with significant differences among MSA subgroups
  • MDA5 (+) vs ARS (+): P < 0.01
  • MDA5 (+) vs ARS (+): P < 0.05
  • MDA5 (+) vs ARS (+): P < 0.01
  • MDA5 (+) vs ARS (+): P < 0.05

Observational data: associations, not effects.

Further findings

Interferon-stimulated gene (ISG) expression and cytokines by disease activity

ISG expression and cytokine levels upregulated in IIM; active disease showed significantly higher levels of certain ISGs and cytokines vs clinically stable patients

Correlation of NVC scores with ISGs and cytokines

Microhemorrhage, capillary dilation and capillary density positively correlated with MX1, IFI27, IP-10, RANTES and GROα
P < 0.05
Giant capillary related to IFI27, SDF-1α, IP-10, RANTES and GROα
P < 0.05

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Nailfold videocapillaroscopy findings are associated with IIM subtypes and IFN activation. Arthritis Res Ther. Published 20 March 2025. doi:10.1186/s13075-025-03532-9

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.